Moody's follows S&P lead, lowers GE credit rating

March 24, 2009 at 1:36AM

NEW YORK - General Electric Co. lost its top credit rating from Moody's Investors Service because of higher risks at the conglomerate's struggling GE Capital lending unit.

The expected move follows a similar downgrade of GE this month by ratings agency Standard & Poor's.

Moody's lowered its ratings for GE and GE Capital two notches to "Aa2" from "Aaa." It said the outlook for both is stable. The downgrades mean GE will likely pay higher costs to borrow money.

GE Capital, which recently made up nearly half of GE's overall earnings, has been hammered by the financial crisis. GE said last week the finance unit could end up just breaking even this year because of higher losses on loans for credit cards, overseas mortgages, big equipment and commercial property.

GE had forecast earlier that GE Capital would have earnings of around $5 billion.

Moody's said GE's industrial businesses, which include energy equipment, machines for health care and jet engines, would still likely warrant the top credit rating on their own. But the lower overall rating was warranted because of the volatility of GE Capital's earnings and questions over its funding, according to Moody's.

GE said in a statement that the downgrade, along with the S&P cut, would not have a significant impact on its operations or funding.

The company noted that both ratings agencies gave it a "stable" outlook, meaning a further downgrade is unlikely in the short term.

"This action was not unexpected in the current environment, and while no one likes a downgrade, Moody's, like S&P, confirmed the fundamental soundness of GE Capital and the strength our industrial businesses," GE Chairman and CEO Jeff Immelt said in a statement.

Shares of GE rose 89 cents, or 9.3 percent, to $10.43 Monday.

ASSOCIATED PRESS

about the writer

about the writer

More from Business

See More
card image
Provided by Exact Sciences

The late Dr. David Ahlquist co-invented ColoGuard, which is helping drive Abbott Laboratories’ acquisition of Exact Sciences. After an ALS diagnosis in 2019, Ahlquist wasn’t done inventing.

card image
card image